Voyager Therapeutics (VYGR) to Release Earnings on Monday

Voyager Therapeutics (NASDAQ:VYGR) is anticipated to release its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Voyager Therapeutics to post earnings of ($0.54) per share and revenue of $8.1710 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.08. The company had revenue of $13.46 million for the quarter, compared to the consensus estimate of $10.49 million. Voyager Therapeutics had a negative net margin of 296.53% and a negative return on equity of 51.35%. On average, analysts expect Voyager Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Voyager Therapeutics Stock Performance

VYGR opened at $3.76 on Monday. The company has a market cap of $227.18 million, a price-to-earnings ratio of -1.85 and a beta of 1.26. The company’s 50 day moving average is $4.01 and its 200 day moving average is $4.08. Voyager Therapeutics has a 12-month low of $2.64 and a 12-month high of $5.55.

Insider Activity

In other news, CEO Alfred Sandrock sold 11,511 shares of Voyager Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total transaction of $44,547.57. Following the sale, the chief executive officer owned 472,549 shares in the company, valued at $1,828,764.63. This trade represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 61,294 shares of company stock worth $233,241 in the last quarter. Company insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Invesco Ltd. raised its position in shares of Voyager Therapeutics by 28.2% during the fourth quarter. Invesco Ltd. now owns 116,000 shares of the company’s stock valued at $456,000 after buying an additional 25,522 shares during the last quarter. Hsbc Holdings PLC raised its position in shares of Voyager Therapeutics by 118.5% during the second quarter. Hsbc Holdings PLC now owns 148,377 shares of the company’s stock valued at $440,000 after buying an additional 80,474 shares during the last quarter. American Century Companies Inc. raised its position in shares of Voyager Therapeutics by 5.1% during the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock valued at $430,000 after buying an additional 6,748 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Voyager Therapeutics during the fourth quarter valued at approximately $219,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Voyager Therapeutics during the first quarter valued at approximately $218,000. Institutional investors own 48.03% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on VYGR. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, March 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Wednesday, April 15th. Wall Street Zen raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Truist Financial raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.